Japanese Journal of Clinical Oncology 34:14-19 (2004)
© 2004 Foundation for Promotion of Cancer Research
Radical Cystectomy for Invasive Bladder Cancer: Results of Multi-institutional Pooled Analysis
Departments of Urology, 1 Sapporo Medical University School of Medicine, 2 Shizuoka Cancer Center Hospital, 3 Hokkaido University Graduate School of Medicine, 4 Akita University School of Medicine, 5 Niigata University Graduate School of Medicine and Dental Sciences, 6 Niigata Cancer Center Hospital, 7 Shinshu University School of Medicine, 8 Chiba University Graduate School of Medicine, 9 National Cancer Center Hospital, 10 Tokyo Women’s Medical University School of Medicine, 11 Toranomon Hospital, 12 Mie University Faculty of Medicine, 13 Nagoya University Gradate School of Medicine, 14 Nissei Hospital, 15 Kyoto University Graduate School of Medicine, 16 Nara Medical University, 17 Japan Red Cross Wakayama Medical Center, 18 Okayama University Graduate School of Medicine and Dentistry, 19 Kagawa University Faculty of Medicine, 20 Tohoku University Graduate School of Medicine, 21 Kumamoto University School of Medicine and 22 Kagoshima University School of Medicine, Japan
Background: We report the outcome of radical cystectomy for patients with invasive bladder cancer, who did not have regional lymph node or distant metastases, at 21 hospitals.
Methods: Retrospective, non-randomized, multi-institutional pooled data were analyzed to evaluate outcomes of patients who received radical cystectomy. Between 1991 and 1995, 518 patients with invasive bladder cancer were treated with radical cystectomy at 21 hospitals. Of these, 250 patients (48.3%) received some type of neoadjuvant and/or adjuvant therapy depending on the treatment policy of each hospital.
Results: The median follow-up period was 4.4 years, ranging from 0.1 to 11.4 years. The 5-year overall survival rate was 58% for all 518 patients. The 5-year overall survival rates for patients with clinical T2N0M0, T3N0M0 and T4N0M0 were 67%, 52% and 38%, respectively. The patients with pT1 or lower stage, pT2, pT3 and pT4 disease without lymph node metastasis had 5-year overall survivals of 81%, 74%, 47% and 38%, respectively. The patients who were node positive had the worst prognosis, with a 30% overall survival rate at 5 years. Neoadjuvant or adjuvant chemotherapy did not provide a significant survival advantage, although adjuvant chemotherapy improved the 5-year overall survival in patients with pathologically proven lymph node metastasis.
Conclusions: The current retrospective study showed that radical cystectomy provided an overall survival equivalent to studies reported previously, but surgery alone had no more potential to prolong survival of patients with invasive cancer. Therefore, a large-scale randomized study on adjuvant treatment as well as development of new strategies will be needed to improve the outcome for patients with invasive bladder cancer.
+ Present address: Yamagata University School of Medicine
For reprints and all correspondence: Taiji Tsukamoto, Department of Urology, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-Ku, Sapporo 060-8543, Japan. E-mail: taijit{at}sapmed.ac.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Hashine, Y. Kusuhara, N. Miura, A. Shirato, Y. Sumiyoshi, and M. Kataoka Bladder Preservation Therapy Conducted by Intra-arterial Chemotherapy and Radiotherapy for Muscle Invasive Bladder Cancer Jpn. J. Clin. Oncol., June 1, 2009; 39(6): 381 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lehmann, M. Retz, C. Wiemers, J. Beck, J. Thuroff, C. Weining, P. Albers, D. Frohneberg, T. Becker, P.-J. Funke, et al. Adjuvant Cisplatin Plus Methotrexate Versus Methotrexate, Vinblastine, Epirubicin, and Cisplatin in Locally Advanced Bladder Cancer: Results of a Randomized, Multicenter, Phase III Trial (AUO-AB 05/95) J. Clin. Oncol., August 1, 2005; 23(22): 4963 - 4974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsukamoto, H. Kitamura, A. Takahashi, and N. Masumori Treatment of Invasive Bladder Cancer: Lessons from the Past and Perspective for the Future Jpn. J. Clin. Oncol., June 1, 2004; 34(6): 295 - 306. [Abstract] [Full Text] [PDF]
|
|